Acquired hemophilia A
别名
AHA、Acquired F8 deficiency、Acquired factor VIII deficiency
基本事实
- 遗传方式
- 不适用
- 发病年龄
- 青少年期、成年期、儿童期、老年期
- 患病率
- 1-9 / 1 000 000(Europe)
近两年的全球研究 267L2
2024/10 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。
- 2026-09病例报告开放获取When A Fall Isn't Just a Fall: Delayed Diagnosis of Acquired Hemophilia A in a Nonagenarian Patient
- 2026-09病例报告Teclistamab in relapsed, multi-refractory acquired hemophilia A after failure of anti-CD19 CAR-T cell therapy
- 2026-09开放获取Time- and Temperature-Dependent Response of Acquired FV Inhibitors: Implications for Laboratory Diagnosis and Clinical Management
- 2026-09综述开放获取Immune Checkpoint Inhibitor-Associated Hemophagocytic Lymphohistiocytosis: A Systematic Review
- 2026-09开放获取Kunihiro Hattori, Tomoyuki Igawa, and Takehisa Kitazawa share Lasker Award honors for revolutionary hemophilia A therapy
- 2026-09Acquired hemophilia: insights from a multicenter real-life study in a middle-income country
- 2026-09Acquired hemophilia A following wasp stings: a case report
- 2026-09Acquired hemophilia A following wasp stings: a case report
- 2026-09系统综述Oral Clues to Undiagnosed Congenital Hemophilia: A Systematic Review of Case Reports
- 2026-09Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue
- 2026-09综述病例报告开放获取Acquired hemophilia a caused by complicated urinary tract infection due to flavobacterium odoratum: A case report and literature review
- 2026-09开放获取Cardiovascular risk scores estimate arterial thrombotic risk in aging adults with hemophilia in the ADVANCE Japan cohort
- 2026-08Remission-driven discontinuation shapes the observed duration of emicizumab in acquired hemophilia A. Comment on: "Short-term emicizumab in patients with acquired hemophilia A"
- 2026-08Mortality and Relapse Patterns in Acquired Hemophilia A: A Single-Centre Experience and Systematic Review With Proportional Meta-Analysis
- 2026-08开放获取Autoimmune Reporting Signals in FAERS Reports Listing COVID-19 Vaccines as Suspect Products: An Active-Comparator Disproportionality Analysis
- 2026-08综述开放获取Targeting CD38 Across Autoimmune and Plasma Cell-Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape
- 2026-08综述开放获取Hematological Toxicities in the Modern Era of Melanoma Therapy
- 2026-08病例报告Case Report: When Routine Gynecologic Procedures Unmask a Systemic Bleeding Disorder: Refractory Uterine Hemorrhage Leading to the Diagnosis of AL Amyloidosis
- 2026-07病例报告开放获取Acquired Hemophilia A in an Elderly Patient Receiving Clopidogrel: Drug-Induced or Age-Associated Autoimmunity?
- 2026-07开放获取Hematoma, Hemarthrosis, and Hemotympanum: A Case Report of Acquired Hemophilia A
国家医保药品目录中点名本病的药品 1L2
出自《国家基本医疗保险、生育保险和工伤保险药品目录(2025年)》(医保发〔2025〕33号,2026-01-01 起执行)。下列药品在药品名称或限定支付范围里出现了本病的名称。
匹配不到 ≠ 不能报销。目录里只有约一成药品设了限定支付范围,其余按适应症正常使用同样可报销;本区块只能回答「目录有没有点名这个病」,不能回答「这个病有没有药能报销」。各省执行细则、双通道与单独支付范围另有规定,请以当地医保部门口径为准。
- 注射用重组人凝血因子Ⅶa乙类西药限下列患者群体出血的治疗,以及外科手术或有创操作出血的防治:1.凝血因子Ⅷ或Ⅸ的抑制物>5个Bethesda单位(BU)的先天性血友病患者;预计对注射凝血因子Ⅷ或凝血因子Ⅸ,具有高记忆应答的先天性血友病患者;2.获得性血友病患者;3.先天性凝血因子Ⅶ(FⅦ)缺乏症患者;4.具有血小板膜糖蛋白Ⅱb-Ⅲa(GPⅡb-Ⅲa)和/或人白细胞抗原(HLA)抗体和既往或现在对血小板输注无效或不佳的血小板无力症患者。
在中国开展的临床试验 6L2
按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。
登记为可入组 3
- 招募中NCT05849740An Exploratory Study of Cluster of Differentiation 38 (CD38) Monoclonal Antibody Combined Corticosteroid in Acquired Hemophilia A中国研究中心 1 个:Tianjin
- 招募中NCT06727669Longitudinal Cohort of Thrombosis and Hemostasis Diseases中国研究中心 5 个:Beijing、Chongqing、Zhengzhou
- 尚未开始招募NCT07789587A Study of Bometase Alfa for Bleeding Control in Acquired Hemophilia A中国研究中心 1 个:Tianjin
其他状态的试验(3 项)
- 状态未知NCT00797381Efficacy and Safety of MK-0518 in Treatment-Experienced HIV-1 Infected Adult Patients With Hemophilia中国研究中心 1 个:Shanghai
- 已完成NCT03384277Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab中国研究中心 1 个:Tianjin
- 状态未知NCT03700229Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A中国研究中心 1 个:Beijing
中国境外的在招试验 5L2
这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。
韩国1日本1
CT.gov 报告命中 5 项,此处取回并展示最近的 2 项。
- 招募中NCT06550882A Study of OBIZUR in Adults With Acquired Hemophilia A (AHA) in South Korea韩国
- 招募中NCT06461533A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A日本
外部标识与链接
发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
- 中文病名:Orphanet 中文包,冻结于 2020-06-01;本条目在该版本中无中文名
- 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)